Assesment of the Prevalence and Impact of Anemia on Women Hospitalized for Gynecologic Conditions Associated with Heavy Uterine Bleeding.

Morrison, John C.; Patel, Saroj Kumar; Dinh, Quinn

doi:10.1182/blood.v110.11.5167.5167

Cited by 14 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Women withAUB areo ften untreated orinadequately treated foranemia [ 21].AUB impacts women'shealthrelated QoLa nd puts aheavy economicb urden on society [22].…”

Section: Fcm and Ida Duetoaub [6]mentioning

confidence: 99%

Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications

Bailie¹

2011

Arzneimittelforschung

View full text Add to dashboard Cite

Ferric carboxymaltose (FCM, Ferinject) was effective and well tolerated in the treatment of iron-deficiency anemia (IDA) in nine, Phase III, randomized, controlled, multicenter trials in a diverse range of indications, including patients with inflammatory bowel disease (IBD), post-partum anemia (PPA) or abnormal uterine bleeding (AUB), chronic heart failure (CHF), non-dialysis-dependent chronic kidney disease (CKD) and those undergoing hemodialysis (HD). In most trials, patients received either FCM doses of < or = 1000 mg, administered intravenously (i.v.) over < or = 15 min. or oral ferrous sulfate (FeSulf) 325 mg (65 mg iron), three times daily (t.i.d.), or 304 mg (100 mg iron), twice daily (b.i.d.). In one trial, patients on HD received 200 mg i.v. of either FCM or iron sucrose (ISC), two-to-three times weekly. In a pilot study in patients with CHF and CKD, patients received 200 mg of FCM by push injection compared with 200 mg of ISC slow injection. FCM was usually administered until the patient's calculated total iron replacement dose was achieved. Treatment with FCM improved indices of anemia (hemoglobin [Hb], ferritin and transferrin saturation [TSAT] values). In patients on HD with IDA secondary to CKD, FCM demonstrated comparable efficacy to ISC in achieving an increase in Hb. In patients with IBD or PPA, improvements in Hb levels were more rapid with FCM than with FeSulf. Patients with PPA receiving FCM compared with those receiving oral iron achieved an Hb rise > or = 2.0 g/dl earlier (7 days compared with 14 days; p < 0.001), were more likely to achieve an Hb rise > or = 3.0 g/dl at any time beginning at day 14 (86.3% compared with 60.4%; p < 0.001), and achieve an Hb > 12.0 g/dl at the end of the study (Day 42; 90.5% compared with 68.6%, p < 0.01). Serum ferritin increased in the i.v. FCM treatment group, but not in the oral iron group. Differences between groups were significant at each study interval. TSAT increased significantly at every interval in both groups; however, FCM-treated patients showed higher TSAT at each interval after the first week. FCM improved patient quality of life to an equivalent extent to oral FeSulf in patients with IBD or PPA, and to a greater extent than oral FeSulf in women with AUB. FCM also improved quality of life as well as functional symptoms and exercise capacity in patients with CHF. Safety data from more than 3000 patients showed that FCM was well tolerated. No safety concerns have been identified in breastfed infants of mothers receiving FCM. FCM is, therefore, an effective and well-tolerated option in the treatment of IDA.

show abstract

“…Women withAUB areo ften untreated orinadequately treated foranemia [ 21].AUB impacts women'shealthrelated QoLa nd puts aheavy economicb urden on society [22].…”

Section: Fcm and Ida Duetoaub [6]mentioning

confidence: 99%

Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications

Bailie¹

2011

Arzneimittelforschung

View full text Add to dashboard Cite

show abstract

“…Iron-deficiency anaemia is an associated complication (Napolitano et al, 2014) that may cause such women to experience fatigue and lethargy (Andrews, 2009). In severe cases, haemoglobin can drop to dangerous levels (Chapple, 1998) and these women may have to be admitted for hospitalisation and require blood transfusions and management (Harris, 1957;Morrison et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Perspectives of women experiencing Menorrhagia: A descriptive qualitative study

Kamaludin

Zhang

Shorey

2019

Journal of Clinical Nursing

View full text Add to dashboard Cite

Objective To describe the perspectives and support needs of women experiencing menorrhagia in Singapore. Background Women with menorrhagia lack awareness regarding the severity of menorrhagia. There is a dearth of literature understanding the support needs of women with menorrhagia. Design A descriptive qualitative study design was adopted. The Consolidated crieteria for Reportig Qualitative Research (COREQ) was used to report the findings of this study. Methods The study was conducted at a tertiary public hospital in Singapore from July 2017–October 2017. Semi‐structured interviews were used to collect data from 16 women who were diagnosed with menorrhagia. The total number of interviews was concluded based on data saturation. The interviews were transcribed verbatim, and thematic analysis was used to analyse the interview transcripts. The COREQ was used to report the findings of this study. Results Participants reported that they were unaware about menorrhagia and its severity. Various internal and external factors influenced the participants’ awareness and understanding of menorrhagia. Although the participants received support to cope with menorrhagia, the support was deemed insufficient. The women shared that menorrhagia had affected their lives physically, emotionally, socially and financially. They used both external and internal coping mechanisms to cope with their conditions and looked for information through close contacts and the Internet. They longed to learn more about their conditions. Conclusion Multiethnic Singaporean women with menorrhagia lacked awareness about their conditions and the severity, which affected their lives negatively. There should be greater efforts to raise the public's awareness of menorrhagia so that women can seek medical help early and minimise its negative influence on their lives. Relevance to clinical practice Healthcare providers need to pay greater attention to menorrhagia in order to provide more holistic care and support for those experiencing this condition. Healthcare professionals should understand their patients’ experiences with menorrhagia and evaluate their current support resources in order to create a strong support system.

show abstract

“…Indeed, HMB is recognized as the primary cause of iron deficiency and iron‐deficiency anemia among women in routine clinical practice [15]. In a large US survey of hospital inpatients [16], 25% of all women hospitalized for gynecologic disorders associated with HMB were found to be anemic. HMB clearly warrants careful management, and effective treatments are available to alleviate symptoms and improve quality of life [2,10,17].…”

Section: Introductionmentioning

confidence: 99%

Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey

Fraser

Mansour

Breymann

et al. 2014

Intl J Gynecology & Obste

185

157

View full text Add to dashboard Cite

show abstract

Assesment of the Prevalence and Impact of Anemia on Women Hospitalized for Gynecologic Conditions Associated with Heavy Uterine Bleeding.

Cited by 14 publications

References 0 publications

Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications

Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications

Perspectives of women experiencing Menorrhagia: A descriptive qualitative study

Prevalence of heavy menstrual bleeding and experiences of affected women in a European patient survey

Contact Info

Product

Resources

About